B-cells can predict the response of immunotherapy.

Three papers published this week in nature suggest that B cells in larger immune clusters can be used to predict the positive response of some cancer patients to immunotherapy.the results may help to improve patient care and assist in the development of therapeutic reagents.the patient's immune system can be mobilized to fight cancer.although this approach advances cancer treatment, only 20% of patients can obtain sustained clinical benefits, which also inspires researchers to look for biomarkers that can predict the long-term response of treatment.paper of nature: B cells are associated with survival and immune response in sarcoma, read the full text → → nature: B cells and periodic lymphoid structures promote immune response Long press and recognize the right two-dimensional code and read the full text → these three independent studies have shown that when B cells (components of the immune system) form clusters called "tertiary lymphoid structures", their response to immunotherapy is also enhanced.according to wolf Fridman et al. Of the University of Pittsburgh in Pennsylvania, Jennifer Wargo of Anderson Cancer Center, University of Texas, USA, and G ü ran J ü nsson of Lund University, Sweden, reported that this effect occurred in metastatic melanoma, soft tissue sarcoma and renal cell carcinoma.polyhedral B cells in tumor microenvironment.| source: tullia C. Bruno, a new potential biomarker, complements an increasing number of clinical prognostic indicators, including increased immune activity, mutation burden, and patient microbiome composition.currently, the immunotherapy approved by the food and Drug Administration (FDA) mainly enhances the activity of another group of immune cells (killer T cells), and the latest research highlights the potential therapeutic value of targeting multiple immune cells.© natureNature | DOI: 10.1038/s41586-019-1906-8Nature | DOI: 10.1038/s41586-019-1922-8Nature | DOI: 10.1038/s41586-019-1914-8